Katie Planey

Company: Acelot, Inc.

Job title: Chief Executive Officer & Board Member

Seminars:

Showcasing Preclinical Promise of Targeting TDP-43 in Alzheimer’s Disease 2:30 pm

Reviewing why targeting TDP-43 has historically been difficult Outlining the mechanisms of the small molecule to directly target TDP-43 Characterizing the animal efficacy data Discussing TDP-43 prevalence in AD and future directions for clinical translation of this targetRead more

day: Conference Day Two - Track Two